Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board
December 17, 2024 08:30 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules
December 13, 2024 16:05 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules
December 12, 2024 12:05 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects
December 03, 2024 08:15 ET
|
Palisade Bio, Inc.
First three Single Ascending Dose cohorts demonstrated no treatment related adverse events Carlsbad, CA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,”...
Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit
November 14, 2024 09:00 ET
|
Palisade Bio, Inc.
Presentation to highlight advances in fibrostenotic Crohn’s Disease and the potential of localized PDE4 inhibition Carlsbad, CA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq:...
Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108
November 12, 2024 08:45 ET
|
Palisade Bio, Inc.
Commenced enrollment and dosing in Phase 1 clinical study of PALI-2108 for the treatment of moderate-to-severe Ulcerative Colitis (UC) Carlsbad, CA, Nov. 12, 2024 (GLOBE NEWSWIRE) --...
Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)
November 07, 2024 08:30 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing...
Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology’s (ACG) 2024 Annual Scientific Meeting
October 15, 2024 08:00 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing...
Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)
October 10, 2024 08:30 ET
|
Palisade Bio, Inc.
– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA) – The study is a Phase 1 Single Ascending Dose (SAD)...
Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
October 08, 2024 08:00 ET
|
Palisade Bio, Inc.
– Live webcast fireside chat on Tuesday, October 15th at 4:30 PM ET Carlsbad, CA, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the...